Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial
Zhuravel et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.101169
https://c19early.org/zhuravel.html